<p>GWN Securities Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第三季度减少了对强生（NYSE:JNJ - 免费报告）股票的持有，减幅为 51.6%。该基金在此期间出售了 27,326 股后，持有该公司 25,658 股股票。强生大约占 GWN Securities Inc. 投资组合的 1.1%，是其第 14 大持股。截止最近一个季度，GWN Securities Inc. 在强生的持股价值为 4,790,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>这只 ETF 证明了医疗保健反弹是真实的</li>
</ul>
<p>其他机构投资者和对冲基金最近也增加或减少了对该公司的投资。先锋集团（Vanguard Group Inc.）在第二季度增持了 1.3% 的强生股份。先锋集团目前拥有 237,047,859 股该公司的股票，价值 36,209,060,000 美元，在上个季度又增持了 3,085,180 股。Geode Capital Management LLC 在第二季度将其在强生的持股提高了 2.1%。Geode Capital Management LLC 目前拥有 60,609,476 股该公司的股票，价值 9,227,988,000 美元，在上个季度又购买了 1,225,676 股。挪威银行（Norges Bank）在第二季度获得了强生的新股份，价值约为 4,877,174,000 美元。纽约梅隆银行（Bank of New York Mellon Corp）在第二季度增持了 2.7% 的强生股份。纽约梅隆银行目前拥有 23,802,503 股该公司的股票，价值 3,635,832,000 美元，在上个季度又购买了 620,039 股。最后，查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第二季度将其在强生的持股提高了 0.3%。查尔斯·施瓦布投资管理公司目前拥有 18,951,337 股该公司的股票，价值 2,894,979,000 美元，在上个季度又购买了 52,074 股。目前，69.55% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级调整</h2>
<p>几位股票研究分析师最近对 JNJ 股票发表了评论。BMO Capital Markets 在 12 月 11 日的研究报告中重申了对强生股票的 &#34;跑赢大盘&#34; 评级。Stifel Nicolaus 在 10 月 15 日的研究报告中将强生的目标价从 165.00 美元上调至 190.00 美元，并给予该股票 &#34;持有&#34; 评级。瑞银集团（UBS Group）在 1 月 5 日的研究报告中重申了对强生股票的 &#34;买入&#34; 评级。加拿大皇家银行（Royal Bank Of Canada）在 12 月 17 日的报告中设定了强生的目标价为 240.00 美元。最后，摩根士丹利（Morgan Stanley）在 12 月 12 日的报告中将强生的目标价从 190.00 美元上调至 197.00 美元，并给予该股票 &#34;等权重&#34; 评级。四位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，强生目前的共识评级为 &#34;适度买入&#34;，平均目标价为 213.33 美元。</p>
<ul>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
</ul>
<p><strong>查看我们最新的 JNJ 股票报告</strong></p>
<h2>强生股票表现</h2>
<p>NYSE JNJ 周五开盘价为 218.81 美元。该公司的市值为 5271.8 亿美元，市盈率为 21.12，市盈增长比率为 2.26，贝塔值为 0.34。该股票的 50 日简单移动平均线为 205.82 美元，200 日简单移动平均线为 186.74 美元。公司的债务与股本比率为 0.50，速动比率为 0.80，流动比率为 1.07。强生的 52 周低点为 141.50 美元，52 周高点为 220.11 美元。</p>
<ul>
<li>辉瑞增加对减肥药的重大投资</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）在 10 月 14 日星期二发布了其财报。该公司报告本季度每股收益为 2.80 美元，超出市场共识预期的 2.76 美元，超出 0.04 美元。该公司本季度的收入为 239.9 亿美元，而分析师预期为 237.3 亿美元。强生的股本回报率为 32.73%，净利润率为 27.26%。强生本季度的收入同比增长 6.8%。去年同期，该公司每股收益为 2.42 美元。平均而言，股票分析师预测强生在当前年度的每股收益将达到 10.58 美元。</p>
<h2>强生股息公告</h2>
<p>该公司最近还披露了季度股息，将于 3 月 10 日星期二支付。记录在案的股东将在 2 月 24 日星期二获得 1.30 美元的股息。这代表着 5.20 美元的年化股息和 2.4% 的收益率。除息日期为 2 月 24 日星期二。强生的股息支付比率目前为 50.19%。</p>
<h2>关于强生</h2>
<p>（免费报告）</p>
<p>强生是一家总部位于新泽西州新布伦瑞克的跨国医疗保健公司，开发、生产和销售广泛的产品，涵盖制药、医疗设备和以前的消费健康。该公司由约翰逊家族于 1886 年创立，已发展成为一个在全球多个国家开展业务和销售的全球医疗保健组织。</p>
<p>该公司的制药业务主要在其扬森研究与开发组织下运作，专注于免疫学、传染病、肿瘤学和神经科学等治疗领域的处方药。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>埃隆将 SpaceX 公开上市！$100 的 IPO 前机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
</ul>
<p><strong>想知道其他对 JNJ 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Johnson &amp; Johnson (NYSE:JNJ - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Johnson &amp; Johnson 吗？</h2>
<p>在考虑 Johnson &amp; Johnson 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Johnson &amp; Johnson 并不在名单上。</p>
<p>虽然 Johnson &amp; Johnson 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>GWN Securities Inc. 在第三季度减少了对强生（NYSE: JNJ）51.6% 的持股，目前持有 25,658 股，价值为 479 万美元。其他机构投资者如先锋集团和 Geode Capital 则增加了他们的股份。分析师们维持 “适度买入” 的共识评级，平均目标价为 213.33 美元。强生的股票开盘价为 218.81 美元，市值为 5271.8 亿美元，最近的每股收益为 2.80 美元，超出预期。该公司报告的收入同比增长 6.8%</p>

<p>GWN Securities Inc. lessened its holdings in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 51.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,658 shares of the company's stock after selling 27,326 shares during the period. Johnson &amp; Johnson makes up about 1.1% of GWN Securities Inc.'s portfolio, making the stock its 14th biggest holding. GWN Securities Inc.'s holdings in Johnson &amp; Johnson were worth $4,790,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>GWN Securities Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第三季度减少了对强生（NYSE:JNJ - 免费报告）股票的持有，减幅为 51.6%。该基金在此期间出售了 27,326 股后，持有该公司 25,658 股股票。强生大约占 GWN Securities Inc. 投资组合的 1.1%，是其第 14 大持股。截止最近一个季度，GWN Securities Inc. 在强生的持股价值为 4,790,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>这只 ETF 证明了医疗保健反弹是真实的</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Johnson &amp; Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Johnson &amp; Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company's stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the last quarter. Norges Bank acquired a new stake in Johnson &amp; Johnson in the 2nd quarter worth approximately $4,877,174,000. Bank of New York Mellon Corp boosted its stake in Johnson &amp; Johnson by 2.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company's stock worth $3,635,832,000 after purchasing an additional 620,039 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Johnson &amp; Johnson by 0.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company's stock worth $2,894,979,000 after purchasing an additional 52,074 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也增加或减少了对该公司的投资。先锋集团（Vanguard Group Inc.）在第二季度增持了 1.3% 的强生股份。先锋集团目前拥有 237,047,859 股该公司的股票，价值 36,209,060,000 美元，在上个季度又增持了 3,085,180 股。Geode Capital Management LLC 在第二季度将其在强生的持股提高了 2.1%。Geode Capital Management LLC 目前拥有 60,609,476 股该公司的股票，价值 9,227,988,000 美元，在上个季度又购买了 1,225,676 股。挪威银行（Norges Bank）在第二季度获得了强生的新股份，价值约为 4,877,174,000 美元。纽约梅隆银行（Bank of New York Mellon Corp）在第二季度增持了 2.7% 的强生股份。纽约梅隆银行目前拥有 23,802,503 股该公司的股票，价值 3,635,832,000 美元，在上个季度又购买了 620,039 股。最后，查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第二季度将其在强生的持股提高了 0.3%。查尔斯·施瓦布投资管理公司目前拥有 18,951,337 股该公司的股票，价值 2,894,979,000 美元，在上个季度又购买了 52,074 股。目前，69.55% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several equities research analysts have recently commented on JNJ shares. BMO Capital Markets reiterated an &#34;outperform&#34; rating on shares of Johnson &amp; Johnson in a research note on Thursday, December 11th. Stifel Nicolaus raised their target price on Johnson &amp; Johnson from $165.00 to $190.00 and gave the stock a &#34;hold&#34; rating in a research note on Wednesday, October 15th. UBS Group reaffirmed a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research report on Monday, January 5th. Royal Bank Of Canada set a $240.00 price objective on Johnson &amp; Johnson in a report on Wednesday, December 17th. Finally, Morgan Stanley lifted their target price on Johnson &amp; Johnson from $190.00 to $197.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, December 12th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Johnson &amp; Johnson currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $213.33.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 JNJ 股票发表了评论。BMO Capital Markets 在 12 月 11 日的研究报告中重申了对强生股票的 &#34;跑赢大盘&#34; 评级。Stifel Nicolaus 在 10 月 15 日的研究报告中将强生的目标价从 165.00 美元上调至 190.00 美元，并给予该股票 &#34;持有&#34; 评级。瑞银集团（UBS Group）在 1 月 5 日的研究报告中重申了对强生股票的 &#34;买入&#34; 评级。加拿大皇家银行（Royal Bank Of Canada）在 12 月 17 日的报告中设定了强生的目标价为 240.00 美元。最后，摩根士丹利（Morgan Stanley）在 12 月 12 日的报告中将强生的目标价从 190.00 美元上调至 197.00 美元，并给予该股票 &#34;等权重&#34; 评级。四位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，强生目前的共识评级为 &#34;适度买入&#34;，平均目标价为 213.33 美元。</p>
</div><ul>
<li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
</ul>
<div class="lb-trans"><ul>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 JNJ 股票报告</strong></p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>强生股票表现</h2>
</div><p>NYSE JNJ opened at $218.81 on Friday. The firm has a market capitalization of $527.18 billion, a P/E ratio of 21.12, a PEG ratio of 2.26 and a beta of 0.34. The stock has a 50-day simple moving average of $205.82 and a two-hundred day simple moving average of $186.74. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson &amp; Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $220.11.</p>
<div class="lb-trans"><p>NYSE JNJ 周五开盘价为 218.81 美元。该公司的市值为 5271.8 亿美元，市盈率为 21.12，市盈增长比率为 2.26，贝塔值为 0.34。该股票的 50 日简单移动平均线为 205.82 美元，200 日简单移动平均线为 186.74 美元。公司的债务与股本比率为 0.50，速动比率为 0.80，流动比率为 1.07。强生的 52 周低点为 141.50 美元，52 周高点为 220.11 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞增加对减肥药的重大投资</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 14th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.76 by $0.04. The firm had revenue of $23.99 billion for the quarter, compared to analyst estimates of $23.73 billion. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%.Johnson &amp; Johnson's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period last year, the company earned $2.42 earnings per share. On average, equities analysts forecast that Johnson &amp; Johnson will post 10.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）在 10 月 14 日星期二发布了其财报。该公司报告本季度每股收益为 2.80 美元，超出市场共识预期的 2.76 美元，超出 0.04 美元。该公司本季度的收入为 239.9 亿美元，而分析师预期为 237.3 亿美元。强生的股本回报率为 32.73%，净利润率为 27.26%。强生本季度的收入同比增长 6.8%。去年同期，该公司每股收益为 2.42 美元。平均而言，股票分析师预测强生在当前年度的每股收益将达到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>强生股息公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson &amp; Johnson's dividend payout ratio is currently 50.19%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，将于 3 月 10 日星期二支付。记录在案的股东将在 2 月 24 日星期二获得 1.30 美元的股息。这代表着 5.20 美元的年化股息和 2.4% 的收益率。除息日期为 2 月 24 日星期二。强生的股息支付比率目前为 50.19%。</p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>关于强生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.</p>
<div class="lb-trans"><p>强生是一家总部位于新泽西州新布伦瑞克的跨国医疗保健公司，开发、生产和销售广泛的产品，涵盖制药、医疗设备和以前的消费健康。该公司由约翰逊家族于 1886 年创立，已发展成为一个在全球多个国家开展业务和销售的全球医疗保健组织。</p>
</div><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p>
<div class="lb-trans"><p>该公司的制药业务主要在其扬森研究与开发组织下运作，专注于免疫学、传染病、肿瘤学和神经科学等治疗领域的处方药。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>埃隆将 SpaceX 公开上市！$100 的 IPO 前机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 JNJ 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Johnson &amp; Johnson (NYSE:JNJ - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Johnson &amp; Johnson 吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Johnson &amp; Johnson 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Johnson &amp; Johnson 并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Johnson &amp; Johnson 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GWN Securities Inc. 出售了强生 $JNJ 的股票